SCHEMBL23207756

SCHEMBL23207756

O=C(Nc1ccc(C(F)(F)F)cc1)Nc1c[nH]c2ccc(-c3cncc(CO)c3)cc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STING1 Q86WV6 4/20 0.56
▸ KDR P35968 2/20 0.43
▸ DYRK1A Q13627 2/20 0.43
▸ CLK2 P49760 1/20 0.43
▸ CLK3 P49761 1/20 0.43
▸ AAK1 Q2M2I8 1/20 0.42
▸ GOT1 P17174 1/20 0.42
▸ PIM1 P11309 2/20 0.42
▸ PIM3 Q86V86 2/20 0.42
▸ TRPV1 Q8NER1 1/20 0.42
▸ WNT1 P04628 2/20 0.41
▸ IGF1R P08069 2/20 0.41
▸ IKBKB O14920 1/20 0.41
▸ CHUK O15111 1/20 0.41
▸ LYN P07948 1/20 0.41
▸ SYK P43405 1/20 0.41
▸ MAPK8 P45983 1/20 0.41
▸ MAPK10 P53779 1/20 0.41
▸ EPHX2 P34913 1/20 0.41
▸ RIPK1 Q13546 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23207761 0.89 STING1 (0.52) STING1KDRDYRK1ACLK2CLK3
SCHEMBL23208227 0.88 STING1 (0.62) STING1KDRDYRK1AGOT1TRPV1
SCHEMBL30195943 0.88 STING1 (0.62) STING1KDRDYRK1AGOT1TRPV1
SCHEMBL30195890 0.88 STING1 (0.59) STING1KDRDYRK1AAAK1GOT1
SCHEMBL30195886 0.88 STING1 (0.59) STING1KDRAAK1GOT1TRPV1
SCHEMBL23207762 0.88 STING1 (0.59) STING1KDRAAK1GOT1TRPV1
SCHEMBL23207646 0.88 STING1 (0.59) STING1KDRDYRK1AAAK1GOT1
SCHEMBL23207913 0.88 STING1 (0.62) STING1KDRDYRK1AGOT1TRPV1
SCHEMBL23208069 0.84 STING1 (0.55) STING1KDRDYRK1AAAK1GOT1
SCHEMBL23207767 0.84 STING1 (0.62) STING1KDRDYRK1AAAK1TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-01-05 — — US disclosed
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-01-05 — — US disclosed
WO-2021067801-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2021-04-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 STING1 1/4885KDR 2918/4885DYRK1A 3908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback